Caption: Daria Schabad talks to Zami Abraham, the CEO of Pluristem about the published study in PLOS ONE.
Credit: Pluristem Therapeutics
Caption: Daria Schabad talks to Zami Abraham, the CEO of Pluristem about the published study in PLOS ONE.
Credit: Pluristem Therapeutics